$100 Billion Of US And European Pharmaceutical Company Revenues Threatened By Generic Drugs Forecasts URCH Publishing
The report, published by business information supplier URCH Publishing, notes that the period 2007-11 will see the expiration of patent protection for an average of ten drugs a year in the US. As 2005 saw a decline in the number of NCEs approved down to 18 from 23 in 2004, there is clear evidence that the loss of revenue from patent-protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market.
"There is a considerable difference between the top 20 pharmaceutical companies in both the number of products and the amount of revenues under threat from the potential introduction of generics," said Dr Peter Norman, the report's author. "Neither Amgen, which currently markets only biological products, nor Merck KGaA, whose portfolio is primarily mature products, face any threat from generic competition, while Roche, Bayer-Schering, Abbott and Schering-Plough face limited threats to their revenues," added Dr Norman.
The most severely affected companies are Bristol-Myers Squibb, Takeda, AstraZeneca and Eli Lilly with greater than 40% of their revenues threatened, while Merck and Pfizer both face the serious problem of potential erosion of over 50% of their 2005 revenues.
In 2005 global sales of generic products were estimated to be $65 billion, accounting for 14% of the global healthcare market. The five year period to 2011 could see $20 billion of additional revenues generated by the generics companies, significantly enhancing their growth prospects. Sandoz and Teva could be the beneficiaries of this growth, says the report.
The 130 page 'Competition 2007 to 2011' uses detailed regulatory and company source information to provide a concise over of the effect of patent expiries on over 50 major selling pharmaceuticals including, Advair, Gemzar, Risperdal and Zyrtec. More information about the report can be found here.
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry. For more information contact URCH Publishing on (UK) +44 (0) 20 7060 1099.
URCH PUBLISHING LTD
http://www.urchpublishing.com
View drug information on Gemzar; Risperdal Oral Formulation; Zyrtec.
100 de miliarde de $ SUA ºi veniturilor companiei farmaceutice europene ameninþate de medicamente generice de previziuni URCH de publicare - $100 Billion Of US And European Pharmaceutical Company Revenues Threatened By Generic Drugs Forecasts URCH Publishing - articole medicale engleza - startsanatate